JUDGMENT

Prathiba M. Singh, J. (Oral)

1. This hearing has been done through hybrid mode.

I.A. 13062/2023 in C.O.(COMM.IPD-PAT) 3/2022

I.A.13077/2023 in C.O.(COMM.IPD-PAT) 38/2022

2. These are applications filed by the Respondent No.2 seeking the transfer of the present revocation petitions, thereby consolidating the same with the suits for infringement of Patent no.IN243301 (hereinafter "IN'301"), bearing No. COMS 7/2022^{1[Boehringer Ingelheim Pharma Gmbh & Co. KG & Anr. Vs. MSN Laboratories Pvt. Ltd. & Anr.]} and bearing No. COMS 3/2022^{2[Boehringer Ingelheim Pharma GMBH and Co. and Anr. vs. Macleods Pharmaceuticpals Ltd.]} pending before the High Court of Himachal Pradesh.

3. The case of the Respondent No.2- Applicant who is the assignee of IN'301 is that the suits have been filed by the patentee in respect of the pharmaceutical preparations `LINAGLIPTIN' and variants thereof, covered by the granted patent. It is further stated that in suit no. COMS 7/2022, an ad-interim injunction has been granted on 2nd June, 2022 by the said High Court. Additionally it is submitted that in suit no. COMS 3/2022, vide order dated 21st April 2022, the High Court of Himachal Pradesh made the ad- int